231 related articles for article (PubMed ID: 20663232)
1. TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases.
Seo SB; Hur JG; Kim MJ; Lee JW; Kim HB; Bae JH; Kim DW; Kang CD; Kim SH
Mol Cancer; 2010 Jul; 9():199. PubMed ID: 20663232
[TBL] [Abstract][Full Text] [Related]
2. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinoma.
Lee YK; Lin TH; Chang CF; Lo YL
PLoS One; 2013; 8(11):e82478. PubMed ID: 24303084
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin.
Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
Med Oncol; 2015 Apr; 32(4):133. PubMed ID: 25796504
[TBL] [Abstract][Full Text] [Related]
6. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer.
Liao X; Zhang L; Thrasher JB; Du J; Li B
Mol Cancer Ther; 2003 Nov; 2(11):1215-22. PubMed ID: 14617795
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway.
Kim MJ; Kim HB; Bae JH; Lee JW; Park SJ; Kim DW; Park SI; Kang CD; Kim SH
Biochem Pharmacol; 2009 Sep; 78(6):573-82. PubMed ID: 19464267
[TBL] [Abstract][Full Text] [Related]
8. Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc.
Kim DY; Kim MJ; Kim HB; Lee JW; Bae JH; Kim DW; Kang CD; Kim SH
Biochim Biophys Acta; 2011 Jul; 1812(7):796-805. PubMed ID: 21514380
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
Cenni V; Maraldi NM; Ruggeri A; Secchiero P; Del Coco R; De Pol A; Cocco L; Marmiroli S
Int J Oncol; 2004 Dec; 25(6):1599-608. PubMed ID: 15547696
[TBL] [Abstract][Full Text] [Related]
10. High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde.
Kim HB; Kim MJ; Kim DY; Lee JW; Bae JH; Kim DW; Kang CD; Kim SH
Mol Cancer; 2011 Apr; 10():46. PubMed ID: 21513580
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
12. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression.
Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH
Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887
[TBL] [Abstract][Full Text] [Related]
13. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
14. Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells.
Park SJ; Bijangi-Vishehsaraei K; Safa AR
Int J Biochem Mol Biol; 2010; 1(1):90-100. PubMed ID: 20953314
[TBL] [Abstract][Full Text] [Related]
15. GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.
Beurel E; Kornprobst M; Blivet-Van Eggelpoël MJ; Cadoret A; Capeau J; Desbois-Mouthon C
Int J Oncol; 2005 Jul; 27(1):215-22. PubMed ID: 15942663
[TBL] [Abstract][Full Text] [Related]
16. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
Tong X; Li H
Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
[TBL] [Abstract][Full Text] [Related]
17. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
[TBL] [Abstract][Full Text] [Related]
18. DJ-1 is involved in the multidrug resistance of SGC7901 gastric cancer cells through PTEN/PI3K/Akt/Nrf2 pathway.
Qiu L; Ma Z; Li X; Deng Y; Duan G; Zhao LE; Xu X; Xiao L; Liu H; Zhu Z; Chen H
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(11):1202-1214. PubMed ID: 33079995
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.
Baritaki S; Huerta-Yepez S; Sakai T; Spandidos DA; Bonavida B
Mol Cancer Ther; 2007 Apr; 6(4):1387-99. PubMed ID: 17431117
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway.
Galski H; Oved-Gelber T; Simanovsky M; Lazarovici P; Gottesman MM; Nagler A
Biochem Pharmacol; 2013 Sep; 86(5):584-96. PubMed ID: 23774624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
